Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals.

Arruda MB, Campagnari F, de Almeida TB, Couto-Fernandez JC, Tanuri A, Cardoso CC.

PLoS One. 2016 Sep 20;11(9):e0163170. doi: 10.1371/journal.pone.0163170. eCollection 2016.

2.

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2010 Apr;20(4):217-30. doi: 10.1097/FPC.0b013e328336eee4.

PMID:
20139798
3.

Drug transporters relevant to HIV therapy.

Thomas SA.

J HIV Ther. 2004 Nov;9(4):92-6. Review.

PMID:
15731741
4.

Delavirdine: a review of its use in HIV infection.

Scott LJ, Perry CM.

Drugs. 2000 Dec;60(6):1411-44. Review.

PMID:
11152019
5.

ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.

Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S.

J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.

PMID:
24788661
6.

The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.

Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G.

Br J Clin Pharmacol. 2010 Jan;69(1):95-8. doi: 10.1111/j.1365-2125.2009.03551.x.

7.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

8.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
9.

Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.

Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Décosterd L, Telenti A; Swiss HIV Cohort Study.

Pharmacogenet Genomics. 2005 Sep;15(9):599-608.

PMID:
16041239
10.

[Reverse transcriptase inhibitors, protease inhibitors].

Tachikawa N.

Nihon Rinsho. 2012 Apr;70(4):579-95. Review. Japanese.

PMID:
22568138
11.

Host factors and efficacy of antiretroviral treatment.

Turriziani O, Antonelli G.

New Microbiol. 2004 Apr;27(2 Suppl 1):63-9. Review.

PMID:
15646066
12.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

13.
14.

[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].

Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G.

Infez Med. 2006 Jun;14(2):61-70. Review. Italian.

15.

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.

Scherrer AU, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Calmy A, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS).

PLoS One. 2012;7(11):e50307. doi: 10.1371/journal.pone.0050307. Epub 2012 Nov 26. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/78eea40b-1982-4734-b32e-f94ec6d7b85a.

16.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM.

Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Review.

PMID:
20000887
17.

Impact of genetic factors on dyslipidemia in HIV-infected patients starting antiretroviral therapy.

Egaña-Gorroño L, Martínez E, Cormand B, Escribà T, Gatell J, Arnedo M.

AIDS. 2013 Feb 20;27(4):529-38. doi: 10.1097/QAD.0b013e32835d0da1.

PMID:
23262498
18.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
19.

A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome.

Dahlin A, Wittwer M, de la Cruz M, Woo JM, Bam R, Scharen-Guivel V, Flaherty J, Ray AS, Cihlar T, Gupta SK, Giacomini KM.

Pharmacogenet Genomics. 2015 Feb;25(2):82-92. doi: 10.1097/FPC.0000000000000110.

20.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD004246. doi: 10.1002/14651858.CD004246.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 10;12 :CD004246.

PMID:
21154355

Supplemental Content

Support Center